Selected research
Industry Research
Tumor Treatment Drug Industry Research Report 2026
Market perspective
The global Tumor Treatment Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Tumor Treatment Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Tumor Treatment Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Tumor Treatment Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Tumor Treatment Drug include Astellas, Biogen Idec, Bristol-Myers Squibb, Celgene, Gilead Sciences, Ipsen, Merck & Co., Otsuka and AstraZeneca, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Tumor Treatment Drug market in terms of revenue (US$ million) and, where applicable, service volume (Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Tumor Treatment Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tumor Treatment Drug Market by Company
Astellas
Biogen Idec
Bristol-Myers Squibb
Celgene
Gilead Sciences
Ipsen
Merck & Co.
Otsuka
AstraZeneca
AbbVie
Amgen
Bayer
Pfizer
Eli Lilly
Roche
Merck KGaA
Novartis
Johnson & Johnson
Sanofi
Teva
Eisai
Takeda
Tumor Treatment Drug Segment by Type
Immunotherapy (Biologic Therapy)
Chemotherapy
Hormonal Therapy
Targeted Therapy
Others
Tumor Treatment Drug Segment by Application
Respiratory/Lung Cancer
Prostate Cancer
Breast Cancer
Gastrointestinal Cancer
Blood Cancer
Others
Tumor Treatment Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tumor Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tumor Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tumor Treatment Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Tumor Treatment Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immunotherapy (Biologic Therapy)
- Chemotherapy
- Hormonal Therapy
- Targeted Therapy
- Others
Applications
- Respiratory/Lung Cancer
- Prostate Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Blood Cancer
- Others
Companies covered
- Astellas
- Biogen Idec
- Bristol-Myers Squibb
- Celgene
- Gilead Sciences
- Ipsen
- Merck & Co.
- Otsuka
- AstraZeneca
- AbbVie
- Amgen
- Bayer
- Pfizer
- Eli Lilly
- Roche
- Merck KGaA
- Novartis
- Johnson & Johnson
- Sanofi
- Teva
- Eisai
- Takeda
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Tumor Treatment Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Immunotherapy (Biologic Therapy)
- 2.2.3 Chemotherapy
- 2.2.4 Hormonal Therapy
- 2.2.5 Targeted Therapy
- 2.2.6 Others
- 2.3 Tumor Treatment Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Respiratory/Lung Cancer
- 2.3.3 Prostate Cancer
- 2.3.4 Breast Cancer
- 2.3.5 Gastrointestinal Cancer
- 2.3.6 Blood Cancer
- 2.3.7 Others
- 2.4 Assumptions and Limitations
3 Tumor Treatment Drug Breakdown Data by Type
- 3.1 Global Tumor Treatment Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Tumor Treatment Drug Forecasted Market Size by Type (2027-2032)
4 Tumor Treatment Drug Breakdown Data by Application
- 4.1 Global Tumor Treatment Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Tumor Treatment Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Tumor Treatment Drug Market Perspective (2021-2032)
- 5.2 Global Tumor Treatment Drug Growth Trends by Region
- 5.2.1 Global Tumor Treatment Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Tumor Treatment Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Tumor Treatment Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Tumor Treatment Drug Market Dynamics
- 5.3.1 Tumor Treatment Drug Industry Trends
- 5.3.2 Tumor Treatment Drug Market Drivers
- 5.3.3 Tumor Treatment Drug Market Challenges
- 5.3.4 Tumor Treatment Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Tumor Treatment Drug Players by Revenue
- 6.1.1 Global Top Tumor Treatment Drug Players by Revenue (2021-2026)
- 6.1.2 Global Tumor Treatment Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Tumor Treatment Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Tumor Treatment Drug Head Office and Area Served
- 6.4 Global Tumor Treatment Drug Players, Product Type & Application
- 6.5 Global Tumor Treatment Drug Manufacturers Established Date
- 6.6 Global Tumor Treatment Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Tumor Treatment Drug Market Size (2021-2032)
- 7.2 North America Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Tumor Treatment Drug Market Size by Country (2021-2026)
- 7.4 North America Tumor Treatment Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Tumor Treatment Drug Market Size (2021-2032)
- 8.2 Europe Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Tumor Treatment Drug Market Size by Country (2021-2026)
- 8.4 Europe Tumor Treatment Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Tumor Treatment Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Tumor Treatment Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Tumor Treatment Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Tumor Treatment Drug Market Size (2021-2032)
- 10.2 South America Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Tumor Treatment Drug Market Size by Country (2021-2026)
- 10.4 South America Tumor Treatment Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Tumor Treatment Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Tumor Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Tumor Treatment Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Tumor Treatment Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Astellas
- 12.1.1 Astellas Company Information
- 12.1.2 Astellas Business Overview
- 12.1.3 Astellas Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.1.4 Astellas Tumor Treatment Drug Product Portfolio
- 12.1.5 Astellas Recent Developments
- 12.2 Biogen Idec
- 12.2.1 Biogen Idec Company Information
- 12.2.2 Biogen Idec Business Overview
- 12.2.3 Biogen Idec Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.2.4 Biogen Idec Tumor Treatment Drug Product Portfolio
- 12.2.5 Biogen Idec Recent Developments
- 12.3 Bristol-Myers Squibb
- 12.3.1 Bristol-Myers Squibb Company Information
- 12.3.2 Bristol-Myers Squibb Business Overview
- 12.3.3 Bristol-Myers Squibb Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.3.4 Bristol-Myers Squibb Tumor Treatment Drug Product Portfolio
- 12.3.5 Bristol-Myers Squibb Recent Developments
- 12.4 Celgene
- 12.4.1 Celgene Company Information
- 12.4.2 Celgene Business Overview
- 12.4.3 Celgene Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.4.4 Celgene Tumor Treatment Drug Product Portfolio
- 12.4.5 Celgene Recent Developments
- 12.5 Gilead Sciences
- 12.5.1 Gilead Sciences Company Information
- 12.5.2 Gilead Sciences Business Overview
- 12.5.3 Gilead Sciences Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.5.4 Gilead Sciences Tumor Treatment Drug Product Portfolio
- 12.5.5 Gilead Sciences Recent Developments
- 12.6 Ipsen
- 12.6.1 Ipsen Company Information
- 12.6.2 Ipsen Business Overview
- 12.6.3 Ipsen Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.6.4 Ipsen Tumor Treatment Drug Product Portfolio
- 12.6.5 Ipsen Recent Developments
- 12.7 Merck & Co.
- 12.7.1 Merck & Co. Company Information
- 12.7.2 Merck & Co. Business Overview
- 12.7.3 Merck & Co. Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.7.4 Merck & Co. Tumor Treatment Drug Product Portfolio
- 12.7.5 Merck & Co. Recent Developments
- 12.8 Otsuka
- 12.8.1 Otsuka Company Information
- 12.8.2 Otsuka Business Overview
- 12.8.3 Otsuka Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.8.4 Otsuka Tumor Treatment Drug Product Portfolio
- 12.8.5 Otsuka Recent Developments
- 12.9 AstraZeneca
- 12.9.1 AstraZeneca Company Information
- 12.9.2 AstraZeneca Business Overview
- 12.9.3 AstraZeneca Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.9.4 AstraZeneca Tumor Treatment Drug Product Portfolio
- 12.9.5 AstraZeneca Recent Developments
- 12.10 AbbVie
- 12.10.1 AbbVie Company Information
- 12.10.2 AbbVie Business Overview
- 12.10.3 AbbVie Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.10.4 AbbVie Tumor Treatment Drug Product Portfolio
- 12.10.5 AbbVie Recent Developments
- 12.11 Amgen
- 12.11.1 Amgen Company Information
- 12.11.2 Amgen Business Overview
- 12.11.3 Amgen Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.11.4 Amgen Tumor Treatment Drug Product Portfolio
- 12.11.5 Amgen Recent Developments
- 12.12 Bayer
- 12.12.1 Bayer Company Information
- 12.12.2 Bayer Business Overview
- 12.12.3 Bayer Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.12.4 Bayer Tumor Treatment Drug Product Portfolio
- 12.12.5 Bayer Recent Developments
- 12.13 Pfizer
- 12.13.1 Pfizer Company Information
- 12.13.2 Pfizer Business Overview
- 12.13.3 Pfizer Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.13.4 Pfizer Tumor Treatment Drug Product Portfolio
- 12.13.5 Pfizer Recent Developments
- 12.14 Eli Lilly
- 12.14.1 Eli Lilly Company Information
- 12.14.2 Eli Lilly Business Overview
- 12.14.3 Eli Lilly Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.14.4 Eli Lilly Tumor Treatment Drug Product Portfolio
- 12.14.5 Eli Lilly Recent Developments
- 12.15 Roche
- 12.15.1 Roche Company Information
- 12.15.2 Roche Business Overview
- 12.15.3 Roche Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.15.4 Roche Tumor Treatment Drug Product Portfolio
- 12.15.5 Roche Recent Developments
- 12.16 Merck KGaA
- 12.16.1 Merck KGaA Company Information
- 12.16.2 Merck KGaA Business Overview
- 12.16.3 Merck KGaA Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.16.4 Merck KGaA Tumor Treatment Drug Product Portfolio
- 12.16.5 Merck KGaA Recent Developments
- 12.17 Novartis
- 12.17.1 Novartis Company Information
- 12.17.2 Novartis Business Overview
- 12.17.3 Novartis Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.17.4 Novartis Tumor Treatment Drug Product Portfolio
- 12.17.5 Novartis Recent Developments
- 12.18 Johnson & Johnson
- 12.18.1 Johnson & Johnson Company Information
- 12.18.2 Johnson & Johnson Business Overview
- 12.18.3 Johnson & Johnson Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.18.4 Johnson & Johnson Tumor Treatment Drug Product Portfolio
- 12.18.5 Johnson & Johnson Recent Developments
- 12.19 Sanofi
- 12.19.1 Sanofi Company Information
- 12.19.2 Sanofi Business Overview
- 12.19.3 Sanofi Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.19.4 Sanofi Tumor Treatment Drug Product Portfolio
- 12.19.5 Sanofi Recent Developments
- 12.20 Teva
- 12.20.1 Teva Company Information
- 12.20.2 Teva Business Overview
- 12.20.3 Teva Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.20.4 Teva Tumor Treatment Drug Product Portfolio
- 12.20.5 Teva Recent Developments
- 12.21 Eisai
- 12.21.1 Eisai Company Information
- 12.21.2 Eisai Business Overview
- 12.21.3 Eisai Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.21.4 Eisai Tumor Treatment Drug Product Portfolio
- 12.21.5 Eisai Recent Developments
- 12.22 Takeda
- 12.22.1 Takeda Company Information
- 12.22.2 Takeda Business Overview
- 12.22.3 Takeda Revenue in Tumor Treatment Drug Business (2021-2026)
- 12.22.4 Takeda Tumor Treatment Drug Product Portfolio
- 12.22.5 Takeda Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst